Congress opposes FDA preemption rule
In a Jan. 23 letter to FDA, eight leading members of the House and Senate criticize the agency's proposed rule to limit when a manufacturer can revise product labeling without prior FDA approval. "We are concerned that the intent of this proposal is to protect companies in the pharmaceutical and device industry from being held liable for marketing products they know are unsafe," the letter states. The signatories, including Rep. Henry Waxman, D-Calif., and Sen. Edward Kennedy, D-Mass, request that FDA provide data on labeling revisions. The proposed rule reiterates the agency's position that FDA-approved labeling preempts state tort claims (1"The Pink Sheet" Jan. 21, 2008, p. 21). The issue of preemption is being addressed by the U.S. Supreme Court in several cases, including Wyeth v. Levine...
You may also be interested in...
FDA's proposal to restrict when companies can revise product labeling without first getting agency approval drew a sharp reaction from lawyers involved in product liability litigation
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.